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The implications for health of European Union
enlargement
Challenges and opportunities lie ahead
The European Union has come a long way fromits beginnings in 1957 when six countriessigned the Treaty of Rome, committing
themselves “to lay the foundations of an ever closer
union among the peoples of Europe.”1 This aspiration
has become reality. The original grouping has widened
progressively, to include most of western Europe. It has
also deepened, extending beyond coal and steel
production to an entity with its own flag, foreign policy,
currency, and laws that impinge on almost all areas of
daily life. On 1 May 2004 the European Union will
undergo the latest stage in its evolution over the years
as 10 new countries join it. What impact will this
enlargement have on health and health policy?
Although this is only the latest of a series of
enlargements, this one is very different from those that
have gone before. The most obvious difference is its
scale. Earlier enlargements added between one and
three countries; this one brings 10, increasing the
European Union’s surface area by 34% and its popula-
tion by 28%. A second difference is the level of
development between the existing member states and
those acceding to the union, with the average level of
national wealth in the acceding countries only half that
in the current European Union. A third is the diversity
among the acceding states. Earlier enlargements
involved groups of broadly similar countries, such as
Spain and Portugal in 1986. This enlargement includes
three Baltic states that were part of the Soviet Union till
1991, four former Soviet satellites in central Europe,
one country that emerged from the breakup of
Yugoslavia, and two Mediterranean islands that are
members of the Commonwealth.
Enlargement will almost certainly have implications
for health and health policy.2 However, prediction is an
inexact science. Perhaps the only thing of which one can
be certain is that the Europe of 25 countries will be very
different from the Europe of 15. Beyond that lies a
degree of uncertainty, with dominant political direction
at any time reflecting the electoral cycles in different
countries, as illustrated by the way the result of the recent
Spanish election has shifted the balance of power,
forcing Poland to abandon its opposition to proposed
new voting procedures within the council of ministers.
Bearing this caveat in mind, the new member states,
which will now have a voice in both the council of minis-
ters and the European Parliament, may well take a
different stance from existing member states on the role
of the European Union in policies that promote popula-
tion health. Given the much lower life expectancy in
acceding countries in central Europe, which on current
trends would not be expected to converge with that of
the current European Union before about 2030, we
might expect that they will be more supportive of an
active role for the European Union than are some exist-
ing member states. For example, several, such as Poland,
have adopted policies against smoking that go well
beyond those in most countries of western Europe.3
They will also have views on the current anomalous
situation whereby health services are excluded from
the treaties while almost every element of a health
service—from drugs to health professionals—is subject
to European Union law in the context of competition,
free movement, or other policies.4 This situation will
not be resolved by the current proposals for the new
European convention5; however, the situation now
seems more fluid, and forthcoming negotiations may
have an impact on health competencies. As key
decisions have been made in pursuit of various other
European Union policies, unanticipated consequences
for health can be frequent—as with policies on
movement of professionals or limits on working time.
Several newmember states face the possibility of losing
large numbers of their most skilled health profession-
als as well as the prospect of patients demanding
expensive care abroad.6 They may wish to see future
European Union decisions pay attention to the
implications for health care of policies on freedom of
movement—although this may be resisted by countries
such as the United Kingdom that see enlargement as a
partial answer to a shortage of staff.
The new external frontiers of the enlarged
European Union bring it into direct contact with coun-
tries whose transition during the 1990s has been much
more traumatic than those now joining. Bulgaria and
Romania will be joining the European Union in 2007
but most of the others such as Ukraine, Moldova, and
the countries of the Balkans seem destined to remain
outside for the foreseeable future. These countries face
major health problems.7 From self interest or altruism,
a strong case exists for the enlarged European Union
to take action to narrow the gap with these countries,
supporting policies that will enhance their wealth and
their health.8
Enlargement will have an impact on health policy
in Europe, although not what has been suggested by
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the more xenophobic elements of the British tabloid
press, which have raised the prospect of the NHS being
swamped by migrants from the acceding states while
ignoring the probability that anyone moving to the
United Kingdom is more likely to be providing rather
than receiving health care. Any effects are likely to be
gradual, but in the long term they could be substantial,
albeit in ways that no one can now predict.
Enlargement brings challenges, but also opportunities,
and Europe’s politicians and professional associations
must continue to discuss how the European ideal can
work to promote effective health policies that benefit
all their citizens.
Martin McKee professor of European public health
(martin.mckee@lshtm.ac.uk)
Ellen Nolte lecturer in public health
European Observatory on Health Care Systems, London School of
Hygiene and Tropical Medicine, London WC1E 7HT
Competing interests: None declared.
1 European Community. Treaty establishing the European Community. Rome:
European Community, 1957.
2 McKee M, MacLehose L, Nolte E, eds. Health policy and European Union
enlargement. Buckingham: Open University Press, 2004.
3 Osterberg E, Gilmore A, Zatonski W, Heloma A, Delcheva E, McKee M.
Trade and public health: Alcohol and tobacco. In McKee M, MacLehose
L, Nolte E, eds. Health Policy and European Union Enlargement.
Buckingham: Open University Press, 2004 (in press).
4 McKee M,Mossialos E, Baeten R, eds.The impact of European Union law on
health care systems. Brussels: Peter Lang, 2002.
5 Belcher P, McKee M, Rose T. Is health in the European Convention?
EuroHealth 2003;9:1-4.
6 Krosnar K. Could joining European Union club spell disaster for the new
members? BMJ 2004;328:310.
7 Rechel B, McKee M. Healing the crisis. A prescription for public health action
in south-eastern Europe. London: London School of Hygiene and Tropical
Medicine, 2003.
8 Coker RJ, Atun RA, McKee M. Health care system frailties and public
health control of communicable disease on the European Union’s new
eastern border. Lancet 2004;363:1389-92.
Prevention of respiratory syncytial virus infection
in infants
Palivizumab is effective but too expensive, and vaccines are unavailable as yet
Bronchiolitis due to respiratory syncytial virus ispredictable, occurring during the dark winter intemperate climates and the rainy season in
tropical countries. In the United Kingdom around 20%
of admissions for infections of the lower respiratory
tract in children are due to respiratory syncytial virus.
The annual incidence of hospital admissions related to
respiratory syncytial virus is 28.3 per 1000 for infants,
and 1.3 per 1000 for children aged 1-4 years.1 Interest-
ingly, the number of laboratory reports for respiratory
syncytial virus shows a marked downward trend in
England and Wales from 1990 to 2003 (figures 1 and
2). Although changes in clinical or laboratory practice
may be an influence, data from primary care show a fall
in acute respiratory infections over the same years.2
This is fortunate, as treating respiratory syncytial virus
bronchiolitis remains a good example of therapeutic
nihilism—nothing works except oxygen. Adrenaline,
bronchodilators, steroids, and ribavirin all confer no
real benefit. So if cure does not work, how are we doing
with prevention?
Passive immunisation with the monoclonal anti-
body palivizumab is an option for high risk infants. The
impact respiratory syncytial virus study, a double blind,
placebo controlled, randomised study, showed that
palivizumab was safe and decreased admissions related
to respiratory syncytial virus in infants at high risk.3
The American Academy of Pediatrics revised its guide-
lines for passive immunisation against respiratory syn-
cytial virus in 2003.4 Current recommendations are
that palivizumab should be considered for premature
infants born at less than 32-5 weeks’ gestation or
infants younger than 2 years, with chronic lung disease.
In the United States around 100 000 infants a year
receive palivizumab.
The current NHS guidelines have been formulated
by the joint committee on vaccination and immunisa-
tion of the Department of Health. They note that pal-
ivizumab seems safe, well tolerated, and effective in
reducing admissions to hospital, but it remains very
expensive, at a cost of around £2500 for five doses over
the season for respiratory syncytial virus. In the United
Kingdom, studies on readmission rates with respira-
tory syncytial virus bronchiolitis show that palivizumab
is cost effective only in infants born prematurely with
chronic lung disease receiving oxygen at home.5 The
cost-benefit ratio will shift against palivizumab even
more if it becomes clear that admissions for
bronchiolitis due to respiratory syncytial virus are fall-
ing in parallel with laboratory reports. Recently, a
further study of palivizumab in infants with cardiac
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Fig 1 Laboratory reports of respiratory syncytial virus received by
the Communicable Disease Surveillance Centre and microbiology
laboratories of the Health Protection Agency, by date of specimen in
2003-4 and recent years. Data for 2003-4 are provisional, and
caution should be exercised in interpreting a trend for the most
recent weeks
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